EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Evaluation of the European Society of Cardiology Risk Assessment Score in Incident Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension

Zoe Brown iD, Dylan Hansen, Wendy Stevens, Nava Ferdowsi, Laura Ross iD, Alannah Quinlivan, Joanne Sahhar, Gene-Siew Ngian, Diane Apostolopoulos, Jennifer G Walker, Susanna Proudman, Gim Gee Teng und 3 weitere

Arthritis Care & Research · 2024

DOI: 10.1002/acr.25328 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Arthritis Care & Research, 2024. Verfasst von Zoe Brown und 14 weiteren Autor:innen. Beteiligte Einrichtung: The University of Melbourne at St. Vincent's Hospital and St. Vincent's Hospital Melbourne, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Pulmonary Arterial Hypertension, Natriuretic Peptide, Brain. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Medical Research Council Clinical Scientist Award grant, The University of Melbourne Research Training Program Scholarship, National Health and Medical Research Council of Australia Investigator grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Patients with pulmonary arterial hypertension (PAH) may be stratified as low, intermediate, or high risk of 1‐year mortality. In 2022, the European Society of Cardiology (ESC) updated and simplified its risk stratification tool, based on three variables: World Health Organization functional class, serum N‐terminal pro‐brain type natriuretic peptide and six‐minute walk distance, applied at follow‐up visits, intended to guide therapy over time.

Methods

We applied the 2022 ESC risk assessment tool at baseline and follow‐up (within 2 years) to a multinational incident cohort of systemic sclerosis‐associated PAH (SSc‐PAH). Kaplan‐Meier curves, Cox hazards regression, and accelerated failure time models were used to evaluate survival by risk score.

Results

At baseline (n = 260), the majority of SSc‐PAH (72.2%) were graded as intermediate risk of death according to the 2022 tool. At follow‐up, according to 2022 tool, half (55.5%) of the cohort were classified as low or intermediate‐low risk. The 2022 risk model at follow‐up was able to differentiate survival between risk strata. All three individual parameters (World Health Organization functional class, N‐terminal pro‐brain type natriuretic peptide, six‐minute walk distance) were significantly associated with mortality at baseline and/or follow‐up.

Conclusion

The 2022 ESC risk assessment strategy applied at baseline and follow‐up predicts survival in SSc‐PAH. Treatment decisions for SSc‐PAH should include risk assessments, aiming to achieve low‐risk status according to the 2022 ESC guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Scleroderma, SystemicPulmonary Arterial HypertensionNatriuretic Peptide, BrainHumansFemaleMaleRisk AssessmentMiddle AgedAgedAdultRisk FactorsWalk TestPeptide FragmentsIncidenceEuropePrognosisPredictive Value of TestsSocieties, MedicalBiomarkers

Substanzen

Natriuretic Peptide, Brainpro-brain natriuretic peptide (1-76)Peptide FragmentsBiomarkers

Autor:innen und Institutionen

  • The University of Melbourne at St. Vincent's Hospital and St. Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
  • St. Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
  • Monash Health and Monash University, Clayton, Victoria, Australia.
  • Royal Adelaide Hospital, Adelaide, South Australia, Australia, University of Adelaide, North Adelaide, South Australia, Australia, and Flinders Medical Centre, Bedford Park, South Australia, Australia.
  • Royal Adelaide Hospital, Adelaide, South Australia, Australia, and University of Adelaide, North Adelaide, South Australia, Australia.
  • Alexandra Hospital, National University Health System, Singapore, Singapore.

ORCID-Profile: Zoe Brown, Laura Ross, Kathleen Morrisroe

Förderung

  • National Medical Research Council Clinical Scientist Award grant
  • The University of Melbourne Research Training Program Scholarship
  • National Health and Medical Research Council of Australia Investigator grant
  • Reverie Rheumatology Research Fund
  • Scleroderma Australia
  • Scleroderma Victoria
  • Arthritis Australia
  • Australian Rheumatology Association

Zitieren

APA

Brown, Z., Hansen, D., Stevens, W., Ferdowsi, N., Ross, L., Quinlivan, A., Sahhar, J., Ngian, G. S., Apostolopoulos, D., Walker, J. G., Proudman, S., Teng, G. G., Low, A. H. L., Morrisroe, K., & Nikpour, M. (2024). Evaluation of the European Society of Cardiology Risk Assessment Score in Incident Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension. Arthritis Care & Research. https://doi.org/10.1002/acr.25328

Vancouver

Brown Z, Hansen D, Stevens W, Ferdowsi N, Ross L, Quinlivan A, et al. Evaluation of the European Society of Cardiology Risk Assessment Score in Incident Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension. Arthritis Care & Research. 2024. doi:10.1002/acr.25328

BibTeX
@article{Brown2024,
  author = {Brown, Zoe and Hansen, Dylan and Stevens, Wendy and Ferdowsi, Nava and Ross, Laura and Quinlivan, Alannah and Sahhar, Joanne and Ngian, Gene-Siew and Apostolopoulos, Diane and Walker, Jennifer G and Proudman, Susanna and Teng, Gim Gee and Low, Andrea H L and Morrisroe, Kathleen and Nikpour, Mandana},
  title = {Evaluation of the European Society of Cardiology Risk Assessment Score in Incident Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension},
  journal = {Arthritis Care & Research},
  year = {2024},
  doi = {10.1002/acr.25328}
}
Kostenlos starten →